ES2077547T1 - Microesferas de liberacion prolongada que contienen farmaco antipsicotico y procedimiento para prepararlas. - Google Patents

Microesferas de liberacion prolongada que contienen farmaco antipsicotico y procedimiento para prepararlas.

Info

Publication number
ES2077547T1
ES2077547T1 ES93924827T ES93924827T ES2077547T1 ES 2077547 T1 ES2077547 T1 ES 2077547T1 ES 93924827 T ES93924827 T ES 93924827T ES 93924827 T ES93924827 T ES 93924827T ES 2077547 T1 ES2077547 T1 ES 2077547T1
Authority
ES
Spain
Prior art keywords
microsphere
preparing
procedure
biocompatible polymer
prolonged release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES93924827T
Other languages
English (en)
Other versions
ES2077547T3 (es
Inventor
Shigemi Yoshitomi Pharmac Kino
Tomonori Yoshitomi Pha Osajima
Hiroaki Yoshitomi Pharm Mizuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Yoshitomi Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18255017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2077547(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yoshitomi Pharmaceutical Industries Ltd filed Critical Yoshitomi Pharmaceutical Industries Ltd
Publication of ES2077547T1 publication Critical patent/ES2077547T1/es
Application granted granted Critical
Publication of ES2077547T3 publication Critical patent/ES2077547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

UNA MICROESFERA DE LIBERACION SOSTENIDA PRODUCIDA ENCERRANDO UN ANTIPSICOTICO HIDROFOBICO TAL COMO BROMOPERIDOL O HALOPERIDOL EN UNA BASE QUE COMPRENDE UN POLIMERO BIOCOMPATIBLE TAL COMO ACIDO POLILACTICO O UN COPOLIMERO DE ACIDO LACTICO/ACIDO GLICOLICO. PUEDE EXHIBIR UN DESEADO EFECTO FARMACOLOGICO, DONDE ES NECESARIA UNA ADMINISTRACION DE LARGA DURACION, INYECTANDO DE 1 A 8 SEMANAS, UNA VEZ POR SEMANA, EN LUGAR DE CADA DIA. COMO UN RESULTADO, PUEDE SER ESPERADA UNA IMPORTANTE MEJORA EN LA TOLERANCIA DURANTE TERAPIA SOSTENIDA. ADICIONALMENTE, EL USO DEL POLIMERO BIOCOMPATIBLE SIRVE PARA DISTRIBUIR INTEGRAMENTE CON OPERACIONES QUIRURGICAS TALES COMO IMPLANTACION, FACILIDADES HIPODERMICAS E INYECCION INTRAMUSCULAR JUSTO COMO EL CASO DE INYECCION PROLONGADA, Y SE PUEDE DISPENSAR CON EXTRACCION DE LA MICROESFERA. ADEMAS, LA MICROESFERA PUEDE SER ADMINISTRADA CON POCA AVERSION Y DOLOR.
ES93924827T 1992-11-17 1993-11-15 Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion. Expired - Lifetime ES2077547T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33244192 1992-11-17

Publications (2)

Publication Number Publication Date
ES2077547T1 true ES2077547T1 (es) 1995-12-01
ES2077547T3 ES2077547T3 (es) 2000-06-16

Family

ID=18255017

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93924827T Expired - Lifetime ES2077547T3 (es) 1992-11-17 1993-11-15 Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion.

Country Status (11)

Country Link
US (2) US5656299A (es)
EP (1) EP0669128B1 (es)
KR (1) KR100333115B1 (es)
AT (1) ATE188375T1 (es)
CA (1) CA2148823C (es)
DE (2) DE69327542T2 (es)
DK (1) DK0669128T3 (es)
ES (1) ES2077547T3 (es)
GR (2) GR960300020T1 (es)
PT (1) PT669128E (es)
WO (1) WO1994010982A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
ATE212830T1 (de) * 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
EP0733368A1 (en) * 1995-03-24 1996-09-25 Eli Lilly And Company Granule fomulation for olanzapine
FR2748205A1 (fr) 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
ES2183172T3 (es) * 1996-05-07 2003-03-16 Alkermes Inc Procedimiento para la preparacion de microparticulas.
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6854841B1 (en) * 1998-04-17 2005-02-15 Elesys, Inc. Point-of-incidence ink-curing mechanisms for radial printing
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
GB9817078D0 (en) * 1998-08-05 1998-10-07 Habib Nagy A Device for liver surgery
AU759751B2 (en) * 1998-09-30 2003-05-01 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
IL145069A0 (en) * 1999-02-23 2002-06-30 Angiotech Pharm Inc Pharmaceutical compositions for delivery to an external wall of a body passageway or cavity
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
ES2250502T3 (es) * 2000-12-13 2006-04-16 Merckle Gmbh Microparticulas con un perfil de liberacion mejorado y procedimient0 para su preparacion.
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
ES2385030T3 (es) 2001-06-29 2012-07-17 Medgraft Microtech, Inc. Implantes inyectables biodegradables y procedimientos relacionados con su fabricación y uso
CN1278675C (zh) 2001-07-10 2006-10-11 佳能株式会社 含聚羟基烷醇酸酯的粒状体及其制备方法
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
PT1471887E (pt) 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US6699963B2 (en) * 2002-03-18 2004-03-02 The Procter & Gamble Company Grinding process for plastic material and compositions therefrom
PT1487416E (pt) * 2002-03-26 2010-01-25 Teva Pharma Micropartículas de fármacos
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1595549A4 (en) * 2003-02-19 2010-09-22 Takeda Pharmaceutical DISPERSE FOR PREPARATIONS WITH DELAYED RELEASE
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
KR101242486B1 (ko) * 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CN1968700A (zh) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
DK1742616T3 (en) * 2004-04-30 2015-01-12 Abraxis Bioscience Llc The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
ITMI20042232A1 (it) * 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5405825B2 (ja) * 2005-07-18 2014-02-05 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬剤含有インプラント及びその使用方法
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US7538652B2 (en) * 2006-08-29 2009-05-26 International Business Machines Corporation Electrical component tuned by conductive layer deletion
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
DK2440283T3 (en) 2009-06-09 2018-11-26 Neuronano Ab MICROELECTRODE AND MULTIPLE MICROELECTRODES INCLUDING AGENTS FOR THE RELEASE OF MEDICINAL PRODUCTS IN THE TISSUE
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
HUE066287T2 (hu) 2011-04-25 2024-07-28 Geneora Pharma Shijiazhuang Co Ltd Nyújtott leadású mikroszféra risperidon készítmény
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
KR101738127B1 (ko) * 2014-08-08 2017-05-22 (주)비씨월드제약 약물 함유 서방성 미립자의 제조 방법
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20220257518A1 (en) * 2019-07-12 2022-08-18 G2Gbio, Inc Long-lasting formulation containing rivastigmine, and method for preparing same
CN111991397B (zh) * 2020-10-13 2021-09-10 深圳善康医疗健康产业有限公司 一种氟哌噻吨美利曲辛微球及其制备方法
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
FR2534139B1 (fr) * 1982-10-07 1986-08-29 Laruelle Claude Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.

Also Published As

Publication number Publication date
GR960300020T1 (en) 1996-03-31
EP0669128B1 (en) 2000-01-05
KR100333115B1 (ko) 2002-12-02
CA2148823A1 (en) 1994-05-26
US5871778A (en) 1999-02-16
ES2077547T3 (es) 2000-06-16
GR3033016T3 (en) 2000-08-31
DK0669128T3 (da) 2000-06-19
US5656299A (en) 1997-08-12
DE69327542T2 (de) 2000-07-06
KR950703936A (ko) 1995-11-17
EP0669128A1 (en) 1995-08-30
DE69327542D1 (de) 2000-02-10
EP0669128A4 (en) 1996-09-25
WO1994010982A1 (fr) 1994-05-26
DE669128T1 (de) 1996-03-14
CA2148823C (en) 1999-03-09
PT669128E (pt) 2000-06-30
ATE188375T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
ES2077547T3 (es) Microesfera de liberacion sostenida que contiene un antipsicotico y procedimiento de produccion.
IL78826A0 (en) Sustained release pharmaceutical compositions incorporating degradable delivery system of drugs
EP1201241B1 (en) Compositions containing capsaicin or capsaicin analogues and an anesthetic
AU679706B2 (en) Syringe
ATE122879T1 (de) Verabreichungsformen für pharmaka.
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
ATE288258T1 (de) Biodegradierbare polymerzusammensetzung
ES2009346A6 (es) Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
KR960705512A (ko) 생체적합성 안과용 삽입체(biocompatible ocular implants)
ES2059142T3 (es) Composicion farmaceutica inyectable.
DE69427434T2 (de) Flüssige Copolymere aus E-Caprolacton und Lactide
ES2158101T3 (es) Formulaciones farmaceuticas efervescentes que contienen microcapsulas biodegradables de liberacion controlada.
NZ221390A (en) Biodegradable implant containing estradiol and poly(lactide-co-glycolide) polymer: method of administration and preparation
CA2265561A1 (en) Formulations and methods for providing prolonged local anesthesia
ES2149775T3 (es) Composicion para el tratamiento de tejidos que comprende fibrina o fibrinogeno y un polimero biodegradable y biocompatible.
ATE261278T1 (de) Mikrokapseln zum verabreichen von neuroaktiven wirkstoffen
IL111647A (en) Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation
Yehuda et al. Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine
KaymakÇalan et al. Analgesic effect of Δ9-tetrahydrocannabinol in the dog
FR2686250B1 (es)
DK23588A (da) Peroral laegemiddelform med forsinket frigivelse af virksomt stof
JPS6447715A (en) Improver for ovulation inductive pregnant genital physiological dysfunction
Apruzzese et al. Bupivacaine Release from Biopolymeric Depots for the Alleviation of Postoperative Pain
Hutchinson et al. Pharmaceutical Department and Research Department Imperial Chemical Industries PLC, Pharmaceuticals Division Mereside, Alderley Park Macclesfield, Cheshire SK1O 4TG, UK

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669128

Country of ref document: ES